A biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders - Metabolex, Inc. (205073) – has received its first European patent for metaglidasen (MBX-102), the company's lead drug candidate.
The European patent enhances Metabolex's intellectual property position on metaglidasen, which Metabolex is now evaluating in a pivotal Phase 2/3 trial of type 2 diabetes patients.
The Company has 14 issued patents covering the use of metaglidasen, including four U.S. patents and more than 60 pending patent applications covering the use, manufacture and formulation of metaglidasen.
In June 2006, Metabolex has granted the exclusive license for worldwide development and commercialization of metaglidasen Ortho-McNeil, Inc. (a Johnson & Johnson (NYSE: JNJ) company) via a strategic alliance.
Find more details from the press release.
Comment Preview